Methods of treating human immunodeficiency virus (hiv) disease
AssigneeAbbVie Inc.
InventorsAna Gabriela Pires dos Santos, Preethi Krishnan, Mong-Jen Chen, Aline Goebel, Neha Thakre, Insa Winzenborg, Tanaya Vaidya
Life of this patent
Estimating the term…
Abstract
The invention described herein relates to methods of treating HIV infection comprising administering an anti-PD-1 monoclonal antibody and/or an anti-α4β7 monoclonal antibody.
Claims44
A method of treating human immunodeficiency virus (HIV) infection in a patient infected with HIV-1, the method comprising administering to the patient a therapeutically effective amount of a monoclonal antibody which binds to human programmed death receptor 1 (PD-1),
- wherein the monoclonal antibody which binds to PD-1 is mAb2 which comprises (i) a heavy chain variable region (VH) comprising three CDRs:
- VH CDR #1, VH CDR #2, and VH CDR #3;
- and
- (ii) a light chain variable region (VL) comprising three CDRs:
- VL CDR #1, VL CDR #2, and VL CDR #3, wherein:
- VH CDR#1 is
- (SEQ ID NO:
- 1)
- GYTFTHYGMN;
- VH CDR#2 is
- (SEQ ID NO:
- 2)
- WVNTYTGEPTYADDFKG;
- VH CDR#3 is
- (SEQ ID NO:
- 3)
- EGEGLGFGD;
- VL CDR#1 is
- (SEQ ID NO:
- 4)
- RSSQSIVHSHGDTYLE;
- VL CDR#2 is
- (SEQ ID NO:
- 5)
- KVSNRFS;
- and
- VL CDR#3 is
- (SEQ ID NO:
- 6)
- FQGSHIPVT.
-3. (canceled)
(canceled)
-9. (canceled)
-17. (canceled)
A method of treating human immunodeficiency virus (HIV) infection in a patient infected with HIV-1, the method comprising administering to the patient a therapeutically effective amount of a monoclonal antibody which binds to human α4β7,
- wherein the monoclonal antibody which binds to α4β7 is mAb1 which comprises i) a heavy chain variable region (VH) comprising three CDRs:
- VH CDR #1, VH CDR #2, and VH VDR #3;
- and (ii) a light chain variable region (VL) comprising three CDRs:
- VL CDR #1, VL CDR #2, and VL VDR #3, wherein:
- VH CDR#1 is
- (SEQ ID NO:
- 11)
- GFNIKNTYMH;
- VH CDR#2 is
- (SEQ ID NO:
- 12)
- RIDPAKGHTEYAPKFLG;
- VH CDR#3 is
- VDV;
- VL CDR#1 is
- (SEQ ID NO:
- 13)
- HASQDISDNIG;
- VL CDR#2 is
- (SEQ ID NO:
- 14)
- HGTNLED;
- and
- VL CDR#3 is
- (SEQ ID NO:
- 15)
- VQYAQFPWT.
-20. (canceled)
(canceled)
-26. (canceled)
(canceled)
-34. (canceled)
A method of treating human immunodeficiency virus (HIV) infection in a patient infected with HIV-1, the method comprising:
- administering to the patient a therapeutically effective amount of a first monoclonal antibody which binds to human PD-1;
- and
- administering to the patient a therapeutically effective amount of a second monoclonal antibody which binds to human α4β7.
(canceled)
(canceled)
(canceled)
-45. (canceled)
(canceled)
-51. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-69. (canceled)
Dependencies are inferred from the claim text.